Trial reportScientific reports2021
The effect of botulinum toxin injection dose on the appearance of surgical scar.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Add-on benefits of botulinum toxin type A in combination or sequential therapies for scar management: a systematic review and meta-analysis.Frontiers in pain research (Lausanne, Switzerland) · 2026Pooled it
- A Systematic Review And Meta-Analysis: Botulinum Toxin A Effect on Postoperative Facial Scar Prevention.Aesthetic plastic surgery · 2022Pooled it
- Combination Therapy of Intense Pulsed Light and Fractional Carbon Dioxide Laser Versus Botulinum Toxin Type A in Post-thyroidectomy Scar Prevention: A Prospective, Randomized Controlled Trial.Aesthetic plastic surgery · 2026Trial
- The Effects of Tranexamic Acid Injections on Surgical Scars: A Retrospective Study.Aesthetic plastic surgery · 2026Article
- Skin Temperature as a Marker of Vasomotor Response and Restoration of Blood Flow After Aesthetic Botulinum Toxin Therapy in the Forehead.Life (Basel, Switzerland) · 2026Article
- Chirality-Dependent Supramolecular Biomaterials Remodeling of Scar Microenvironment via Integrin-Mediated Regulation for Hypertrophic Scars Therapy.Nano-micro letters · 2026Article
- Advances in the interplay between mechanical forces and inflammatory immunity in keloid formation.Frontiers in immunology · 2026Review
- Effectiveness of different non-surgical scar reduction methods in post-operative scars: a systematic review and meta-analysis.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Mesenchymal stem cell exosomes regulate TGFβ/Smad3 by decreasing the METTL3-NEAT1 axis to inhibit scar progression after breast surgery.Journal of molecular histology · 2025Article
- The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications.Toxins · 2025Review
- Botulinum toxin type A inhibits the formation of hypertrophic scar through the JAK2/STAT3 pathway.Biomolecules & biomedicine · 2024Article
- The Effect of Botulinum Toxin Type A in the Autologous Fat Grafting: A Review.Journal of cosmetic dermatology · 2024Review
- Prospects for Use of Botulinum Toxin Type A for Prevention of Hypertrophic and Keloid Scars after Surgeries.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India · 2024Article
- Treatment and Improvement of Healing after Surgical Intervention.Healthcare (Basel, Switzerland) · 2023Review
- An Updated Review of Hypertrophic Scarring.Cells · 2023Review
- A Retrospective Self-Controlled Study Evaluating the Prophylactic Effects of CACIPLIQ20 on Postsurgical Scars.Aesthetic surgery journal. Open forum · 2023Article
- Exosome Derived from Mesenchymal Stem Cells Alleviates Hypertrophic Scar by Inhibiting the Fibroblasts via TNFSF-13/HSPG2 Signaling Pathway.International journal of nanomedicine · 2023Article
- Histologic Evaluation of the Effects of Folinic Acid Chitosan Hydrogel and Botulinum Toxin A on Wound Repair of Cleft Lip Surgery in Rats.Journal of functional biomaterials · 2022Article
- COBurns & trauma · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early postoperative injection of botulinum toxin type A (BTxA) can reduce surgical scar hypertrophy. BTxA injection at different time points is associated with different levels of efficacy, but the efficacy of different doses of BTxA for scar management has not investigated. The purpose of this study was to investigate the effect of different doses of BTxA administered early after surgery on scar improvement through a split-scar experiment. The study included 22 patients who underwent surgery between September 2019 and October 2020. High- and low-dose BTxA was randomly administered into each half of the surgical wound closure immediately after surgery. One half of the incision was injected with a low dose (4 U) of BTxA, and the other half was injected with a high dose (8 U). The scars were then evaluated at postoperative 6 months using the modified Stony Brook Scar Evaluation Scale (mSBSES), and patient satisfaction was evaluated using the Visual Analogue Scale (VAS). The occurrence of complications or adverse events was also recorded. Twenty patients completed the study and were analyzed. Compared with the low-dose sides, the high-dose sides had significantly better mSBSES scores and significantly higher VAS scores (p < 0.01, respectively). No serious adverse reactions or post-injection complications were observed. Immediately after the operation, high-dose BTxA (that is within the therapeutic range) injection improved the appearance of postoperative scar more than low-dose injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.